- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, will announce its 2007 second quarter results on Monday, August 6, 2007, after the close of the financial markets.
Following the announcement, Hana Biosciences' management will host a live webcast to include a discussion of earnings and a business update at 5:00pm EDT, 2:00pm PDT. Those interested in hearing management's discussion may join the call by dialing (877) 407-8031 in the U.S./Canada. International participants may access the call by dialing (201) 689-8031. Participants may also access a live webcast of the conference call Hana's website at http://www.hanabiosciences.com .
The business update will focus on our drug candidates utilizing our Optisome(tm) Nanoparticle Technology: Marqibo(r) (vincristine sulfate injection), Alocrest(tm) (vinorelbine tartrate injection), and Topotecan hydrochloride injection. Hana will also provide a brief update on the remainder of its product pipeline including Zensana(tm) (ondansetron HCI) Oral Spray.
A replay of this call will be available for one month by dialing (877) 660-6853 U.S./Canada and (201) 612-7415 for International participants. When prompted, enter Account Number #286 and Conference ID #249279. The webcast will be available via the company's website.
About Hana Biosciences
Hana Biosciences, Inc. (Nasdaq:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at http://www.hanabiosciences.com .
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include without limitation, statements regarding the timing, progress and anticipated results of the clinical development, regulatory processes, potential clinical trial initiations, potential IND and NDA filings and commercialization efforts of Hana's product candidates, including its Marqibo product candidate. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to its other product candidates will be successful, that Hana will be able to obtain regulatory approval of any of its product candidates, and that the results of clinical trials will support Hana's claims or beliefs concerning the effectiveness of its product candidates. Additional risks that may affect such forward-looking statements include Hana's need to raise additional capital to fund its product development programs to completion, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2006 filed with the Securities and Exchange Commission. Hana assumes no obligation to update these statements, except as required by law.
For more information, please click here
Hana Biosciences, Inc.
Investor & Media Contacts:
Remy Bernarda, Director, Investor Relations
Copyright © PrimeNewswireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Nanoscale Trojan horses treat inflammation May 24th, 2016
Programmable materials find strength in molecular repetition May 23rd, 2016
Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015
Haydale Announce Year End Results November 3rd, 2015
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016